Exercise-induced bronchoconstriction update—2016

John M. Weiler, John D. Brannan, Christopher C. Randolph, Teal S. Hallstrand, Jonathan Parsons, William Silvers, William Storms, Joanna Zeiger, David I. Bernstein, Joann Blessing-Moore, Matthew Greenhawt, David Khan, David Lang, Richard A. Nicklas, John Oppenheimer, Jay M. Portnoy, Diane E. Schuller, Stephen A. Tilles, Dana Wallace

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The first practice parameter on exercise-induced bronchoconstriction (EIB) was published in 2010. This updated practice parameter was prepared 5 years later. In the ensuing years, there has been increased understanding of the pathogenesis of EIB and improved diagnosis of this disorder by using objective testing. At the time of this publication, observations included the following: dry powder mannitol for inhalation as a bronchial provocation test is FDA approved however not currently available in the United States; if baseline pulmonary function test results are normal to near normal (before and after bronchodilator) in a person with suspected EIB, then further testing should be performed by using standardized exercise challenge or eucapnic voluntary hyperpnea (EVH); and the efficacy of nonpharmaceutical interventions (omega-3 fatty acids) has been challenged. The workgroup preparing this practice parameter updated contemporary practice guidelines based on a current systematic literature review. The group obtained supplementary literature and consensus expert opinions when the published literature was insufficient. A search of the medical literature on PubMed was conducted, and search terms included pathogenesis, diagnosis, differential diagnosis, and therapy (both pharmaceutical and nonpharmaceutical) of exercise-induced bronchoconstriction or exercise-induced asthma (which is no longer a preferred term); asthma; and exercise and asthma. References assessed as relevant to the topic were evaluated to search for additional relevant references. Published clinical studies were appraised by category of evidence and used to document the strength of the recommendation. The parameter was then evaluated by Joint Task Force reviewers and then by reviewers assigned by the parent organizations, as well as the general membership. Based on this process, the parameter can be characterized as an evidence- and consensus-based document.

Original languageEnglish (US)
Pages (from-to)1292-1295.e36
JournalJournal of Allergy and Clinical Immunology
Volume138
Issue number5
DOIs
StatePublished - Nov 1 2016

Fingerprint

Bronchoconstriction
Asthma
Bronchial Provocation Tests
Exercise-Induced Asthma
Bronchodilator Agents
Respiratory Function Tests
Omega-3 Fatty Acids
Expert Testimony
Mannitol
Advisory Committees
Practice Guidelines
PubMed
Powders
Inhalation
Differential Diagnosis
Joints
Organizations
Pharmaceutical Preparations
Therapeutics

Keywords

  • diagnosis
  • differential diagnosis and therapy
  • exercise-induced asthma
  • Exercise-induced bronchoconstriction
  • exercise-induced bronchoconstriction pathogenesis
  • exercise-induced bronchospasm
  • nonpharmacologic
  • pharmacologic

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

Weiler, J. M., Brannan, J. D., Randolph, C. C., Hallstrand, T. S., Parsons, J., Silvers, W., ... Wallace, D. (2016). Exercise-induced bronchoconstriction update—2016. Journal of Allergy and Clinical Immunology, 138(5), 1292-1295.e36. https://doi.org/10.1016/j.jaci.2016.05.029

Exercise-induced bronchoconstriction update—2016. / Weiler, John M.; Brannan, John D.; Randolph, Christopher C.; Hallstrand, Teal S.; Parsons, Jonathan; Silvers, William; Storms, William; Zeiger, Joanna; Bernstein, David I.; Blessing-Moore, Joann; Greenhawt, Matthew; Khan, David; Lang, David; Nicklas, Richard A.; Oppenheimer, John; Portnoy, Jay M.; Schuller, Diane E.; Tilles, Stephen A.; Wallace, Dana.

In: Journal of Allergy and Clinical Immunology, Vol. 138, No. 5, 01.11.2016, p. 1292-1295.e36.

Research output: Contribution to journalArticle

Weiler, JM, Brannan, JD, Randolph, CC, Hallstrand, TS, Parsons, J, Silvers, W, Storms, W, Zeiger, J, Bernstein, DI, Blessing-Moore, J, Greenhawt, M, Khan, D, Lang, D, Nicklas, RA, Oppenheimer, J, Portnoy, JM, Schuller, DE, Tilles, SA & Wallace, D 2016, 'Exercise-induced bronchoconstriction update—2016', Journal of Allergy and Clinical Immunology, vol. 138, no. 5, pp. 1292-1295.e36. https://doi.org/10.1016/j.jaci.2016.05.029
Weiler JM, Brannan JD, Randolph CC, Hallstrand TS, Parsons J, Silvers W et al. Exercise-induced bronchoconstriction update—2016. Journal of Allergy and Clinical Immunology. 2016 Nov 1;138(5):1292-1295.e36. https://doi.org/10.1016/j.jaci.2016.05.029
Weiler, John M. ; Brannan, John D. ; Randolph, Christopher C. ; Hallstrand, Teal S. ; Parsons, Jonathan ; Silvers, William ; Storms, William ; Zeiger, Joanna ; Bernstein, David I. ; Blessing-Moore, Joann ; Greenhawt, Matthew ; Khan, David ; Lang, David ; Nicklas, Richard A. ; Oppenheimer, John ; Portnoy, Jay M. ; Schuller, Diane E. ; Tilles, Stephen A. ; Wallace, Dana. / Exercise-induced bronchoconstriction update—2016. In: Journal of Allergy and Clinical Immunology. 2016 ; Vol. 138, No. 5. pp. 1292-1295.e36.
@article{db212c83262a4cf480ec1827a5427a09,
title = "Exercise-induced bronchoconstriction update—2016",
abstract = "The first practice parameter on exercise-induced bronchoconstriction (EIB) was published in 2010. This updated practice parameter was prepared 5 years later. In the ensuing years, there has been increased understanding of the pathogenesis of EIB and improved diagnosis of this disorder by using objective testing. At the time of this publication, observations included the following: dry powder mannitol for inhalation as a bronchial provocation test is FDA approved however not currently available in the United States; if baseline pulmonary function test results are normal to near normal (before and after bronchodilator) in a person with suspected EIB, then further testing should be performed by using standardized exercise challenge or eucapnic voluntary hyperpnea (EVH); and the efficacy of nonpharmaceutical interventions (omega-3 fatty acids) has been challenged. The workgroup preparing this practice parameter updated contemporary practice guidelines based on a current systematic literature review. The group obtained supplementary literature and consensus expert opinions when the published literature was insufficient. A search of the medical literature on PubMed was conducted, and search terms included pathogenesis, diagnosis, differential diagnosis, and therapy (both pharmaceutical and nonpharmaceutical) of exercise-induced bronchoconstriction or exercise-induced asthma (which is no longer a preferred term); asthma; and exercise and asthma. References assessed as relevant to the topic were evaluated to search for additional relevant references. Published clinical studies were appraised by category of evidence and used to document the strength of the recommendation. The parameter was then evaluated by Joint Task Force reviewers and then by reviewers assigned by the parent organizations, as well as the general membership. Based on this process, the parameter can be characterized as an evidence- and consensus-based document.",
keywords = "diagnosis, differential diagnosis and therapy, exercise-induced asthma, Exercise-induced bronchoconstriction, exercise-induced bronchoconstriction pathogenesis, exercise-induced bronchospasm, nonpharmacologic, pharmacologic",
author = "Weiler, {John M.} and Brannan, {John D.} and Randolph, {Christopher C.} and Hallstrand, {Teal S.} and Jonathan Parsons and William Silvers and William Storms and Joanna Zeiger and Bernstein, {David I.} and Joann Blessing-Moore and Matthew Greenhawt and David Khan and David Lang and Nicklas, {Richard A.} and John Oppenheimer and Portnoy, {Jay M.} and Schuller, {Diane E.} and Tilles, {Stephen A.} and Dana Wallace",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.jaci.2016.05.029",
language = "English (US)",
volume = "138",
pages = "1292--1295.e36",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Exercise-induced bronchoconstriction update—2016

AU - Weiler, John M.

AU - Brannan, John D.

AU - Randolph, Christopher C.

AU - Hallstrand, Teal S.

AU - Parsons, Jonathan

AU - Silvers, William

AU - Storms, William

AU - Zeiger, Joanna

AU - Bernstein, David I.

AU - Blessing-Moore, Joann

AU - Greenhawt, Matthew

AU - Khan, David

AU - Lang, David

AU - Nicklas, Richard A.

AU - Oppenheimer, John

AU - Portnoy, Jay M.

AU - Schuller, Diane E.

AU - Tilles, Stephen A.

AU - Wallace, Dana

PY - 2016/11/1

Y1 - 2016/11/1

N2 - The first practice parameter on exercise-induced bronchoconstriction (EIB) was published in 2010. This updated practice parameter was prepared 5 years later. In the ensuing years, there has been increased understanding of the pathogenesis of EIB and improved diagnosis of this disorder by using objective testing. At the time of this publication, observations included the following: dry powder mannitol for inhalation as a bronchial provocation test is FDA approved however not currently available in the United States; if baseline pulmonary function test results are normal to near normal (before and after bronchodilator) in a person with suspected EIB, then further testing should be performed by using standardized exercise challenge or eucapnic voluntary hyperpnea (EVH); and the efficacy of nonpharmaceutical interventions (omega-3 fatty acids) has been challenged. The workgroup preparing this practice parameter updated contemporary practice guidelines based on a current systematic literature review. The group obtained supplementary literature and consensus expert opinions when the published literature was insufficient. A search of the medical literature on PubMed was conducted, and search terms included pathogenesis, diagnosis, differential diagnosis, and therapy (both pharmaceutical and nonpharmaceutical) of exercise-induced bronchoconstriction or exercise-induced asthma (which is no longer a preferred term); asthma; and exercise and asthma. References assessed as relevant to the topic were evaluated to search for additional relevant references. Published clinical studies were appraised by category of evidence and used to document the strength of the recommendation. The parameter was then evaluated by Joint Task Force reviewers and then by reviewers assigned by the parent organizations, as well as the general membership. Based on this process, the parameter can be characterized as an evidence- and consensus-based document.

AB - The first practice parameter on exercise-induced bronchoconstriction (EIB) was published in 2010. This updated practice parameter was prepared 5 years later. In the ensuing years, there has been increased understanding of the pathogenesis of EIB and improved diagnosis of this disorder by using objective testing. At the time of this publication, observations included the following: dry powder mannitol for inhalation as a bronchial provocation test is FDA approved however not currently available in the United States; if baseline pulmonary function test results are normal to near normal (before and after bronchodilator) in a person with suspected EIB, then further testing should be performed by using standardized exercise challenge or eucapnic voluntary hyperpnea (EVH); and the efficacy of nonpharmaceutical interventions (omega-3 fatty acids) has been challenged. The workgroup preparing this practice parameter updated contemporary practice guidelines based on a current systematic literature review. The group obtained supplementary literature and consensus expert opinions when the published literature was insufficient. A search of the medical literature on PubMed was conducted, and search terms included pathogenesis, diagnosis, differential diagnosis, and therapy (both pharmaceutical and nonpharmaceutical) of exercise-induced bronchoconstriction or exercise-induced asthma (which is no longer a preferred term); asthma; and exercise and asthma. References assessed as relevant to the topic were evaluated to search for additional relevant references. Published clinical studies were appraised by category of evidence and used to document the strength of the recommendation. The parameter was then evaluated by Joint Task Force reviewers and then by reviewers assigned by the parent organizations, as well as the general membership. Based on this process, the parameter can be characterized as an evidence- and consensus-based document.

KW - diagnosis

KW - differential diagnosis and therapy

KW - exercise-induced asthma

KW - Exercise-induced bronchoconstriction

KW - exercise-induced bronchoconstriction pathogenesis

KW - exercise-induced bronchospasm

KW - nonpharmacologic

KW - pharmacologic

UR - http://www.scopus.com/inward/record.url?scp=84994516248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994516248&partnerID=8YFLogxK

U2 - 10.1016/j.jaci.2016.05.029

DO - 10.1016/j.jaci.2016.05.029

M3 - Article

C2 - 27665489

AN - SCOPUS:84994516248

VL - 138

SP - 1292-1295.e36

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 5

ER -